Crispina Calsada Sells 38,716 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) Stock

Regulus Therapeutics Inc. (NASDAQ:RGLS) CFO Crispina Calsada sold 38,716 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $1.26, for a total transaction of $48,782.16. Following the completion of the sale, the chief financial officer now owns 50,566 shares of the company’s stock, valued at approximately $63,713.16. The trade was a 43.36 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Regulus Therapeutics Stock Up 0.8 %

Shares of NASDAQ RGLS opened at $1.28 on Friday. The company has a market cap of $83.84 million, a price-to-earnings ratio of -1.20 and a beta of 1.60. The firm’s fifty day moving average is $1.52 and its 200 day moving average is $1.58. Regulus Therapeutics Inc. has a 52 week low of $1.08 and a 52 week high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last posted its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). Equities research analysts anticipate that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current year.

Institutional Investors Weigh In On Regulus Therapeutics

Large investors have recently made changes to their positions in the business. Creative Planning bought a new stake in Regulus Therapeutics in the third quarter valued at $26,000. SG Americas Securities LLC bought a new stake in shares of Regulus Therapeutics during the 3rd quarter valued at about $33,000. Jane Street Group LLC purchased a new position in shares of Regulus Therapeutics during the third quarter valued at about $46,000. State Street Corp lifted its holdings in Regulus Therapeutics by 3.5% in the third quarter. State Street Corp now owns 1,000,998 shares of the biopharmaceutical company’s stock worth $1,572,000 after buying an additional 33,496 shares during the period. Finally, Victory Capital Management Inc. boosted its position in Regulus Therapeutics by 10.4% during the 3rd quarter. Victory Capital Management Inc. now owns 398,866 shares of the biopharmaceutical company’s stock valued at $626,000 after acquiring an additional 37,480 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research note on Monday, November 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $10.80.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.